Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney function, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhund, Pardeep S., Solomon, Scott D., Docherty, Kieran F., Heerspink, Hiddo J.L., Anand, Inder S., Böhm, Michael, Chopra, Vijay, de Boer, Rudolf A., Desai, Akshay S., Ge, Junbo, Kitakaze, Masafumi, Merkley, Bela, O'Meara, Eileen, Shou, Morten, Tereshchenko, Sergey, Verma, Subodh, Vinh, Pham Nguyen, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Bengtsson, Olof, Langkilde, Anna Maria, Sjöstrand, Mikaela, McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834909/
https://www.ncbi.nlm.nih.gov/pubmed/33040613
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834909/
https://www.ncbi.nlm.nih.gov/pubmed/33040613
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050391

Ejemplares similares